Pre-market Hot Trades in US Stocks

First Solar is down 3.31% in pre-market trading. Based on recent key news:

1. On July 7, First Solar's Chief Product Officer Patrick James Buehler sold company common stock, leading to a decline in market confidence in the company and a 3.31% drop in stock price.

2. On July 3, Buehler sold 1,600 shares worth $288,000, further exacerbating the selling pressure on the company's stock.

3. On July 8, the House Freedom Caucus expressed dissatisfaction with the 12-month timeline for clean energy projects, affecting market confidence in related industries.

Nextera Energy is down 3.00% in pre-market trading. Based on recent key news:

1. On July 7, analysts indicated that Nextera Energy was not on the recommended list, leading to a decline in market confidence and a 3% drop in stock price.

2. On July 8, the company does not own power generation assets and only distributes electricity, with profits mainly coming from transmission asset usage fees, leading to cautious market sentiment regarding its growth potential.

3. On July 5, analysts suggested there are better investment options, despite Nextera Energy being rated as a moderate buy, affecting investor sentiment.

Top Gainers in Pre-market US Stocks

Endra Life Sciences is up 153.72% in pre-market trading. Based on recent important news:

1. On May 16, Wall Street set a 12-month target price of $50 for Endra Life Sciences, rated as "Buy," driving a significant increase in stock price.

2. On May 21, the overall rise in the innovative drug sector boosted Endra Life Sciences' stock price.

3. On May 21, 3SBio reached a significant deal with Pfizer, enhancing market confidence in the biotech sector.

Masterbeef is up 77.27% in pre-market trading. Based on recent important news:

1. On June 12, MasterBeef Group planned to use IPO funds to expand its restaurant network in Hong Kong and Southeast Asia, driving up stock prices.

2. On June 23, during market fluctuations, increased allocation to defensive sectors pushed related stocks higher.

3. On June 30, profits in the hog sector increased by 38% year-on-year, with macro catalysts driving stock prices upward.

ProKidney is up 60.53% in pre-market trading. Based on recent important news:

1. On January 19, news that Anhui would lead the national biopharmaceutical alliance's centralized procurement triggered stock price fluctuations for innovative drug companies, with ProKidney benefiting from market expectations for biopharmaceutical demand, leading to a significant stock price increase.

2. On January 20, Morgan Stanley released a research report indicating that, despite limited impact from the privatization of Fosun Pharma, market attention to the biotech industry increased, driving ProKidney's stock price up.

3. On January 13, Junshi Biosciences signed a licensing agreement with Abbott, with the market optimistic about the commercialization prospects of biosimilars, indirectly boosting ProKidney's stock price